Figure 12.

Blocking of innate immunoreceptor ligands during NK92-mediated cytolysis. The NALM6 pre-B ALL cell line, with or without bryostatin-treatment, was cultured with NK92 cells at an E:T ratio of 10:1. Treatment groups are arranged according to the blocking agent tested: (A) DNAM-1, (B) NKG2D, (C) NKp30, or (D) anti-ICAM1 antibody as in Figure 11 . Average of 3 replicate wells are shown, with statistical difference between groups plotted, ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (E–H) REH leukemia cells were similarly analyzed.